About Sunesis Pharmaceuticals (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:SNSS
- CUSIP: 86732860
- Web: www.sunesis.com
- Market Cap: $43.5 million
- Outstanding Shares: 23,513,000
- 50 Day Moving Avg: $2.13
- 200 Day Moving Avg: $2.73
- 52 Week Range: $1.84 - $4.45
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.33
- P/E Growth: -0.01
- Annual Revenue: $1.96 million
- Price / Sales: 22.19
- Book Value: ($0.27) per share
- Price / Book: -6.85
- EBITDA: ($34,640,000.00)
- Net Margins: -1,472.94%
- Return on Assets: -112.07%
- Current Ratio: 3.36%
- Quick Ratio: 3.36%
- Average Volume: 150,042 shs.
- Beta: 1.52
- Short Ratio: 5.5
Frequently Asked Questions for Sunesis Pharmaceuticals (NASDAQ:SNSS)
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released its quarterly earnings data on Thursday, July, 27th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.35. During the same period in the prior year, the company posted ($0.12) earnings per share. View Sunesis Pharmaceuticals' Earnings History.
When will Sunesis Pharmaceuticals make its next earnings announcement?
Where is Sunesis Pharmaceuticals' stock going? Where will Sunesis Pharmaceuticals' stock price be in 2017?
2 brokers have issued 12 month target prices for Sunesis Pharmaceuticals' shares. Their predictions range from $3.00 to $3.00. On average, they expect Sunesis Pharmaceuticals' share price to reach $3.00 in the next year. View Analyst Ratings for Sunesis Pharmaceuticals.
What are analysts saying about Sunesis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (10/4/2017)
- 2. Cantor Fitzgerald analysts commented, "Interim data analysis from Phase Ib study of BTK inhibitor SNS-062 is expected in mid-2018, possibly at ASCO." (9/27/2017)
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include Brainstorm Cell Therapeutics (BCLI), ArQule (ARQL), Tissue Regenix Group PLC (TRX), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Vernalis plc (VER), Navidea Biopharmaceuticals (NAVB), CytRx Corporation (CYTR), Prima BioMed Ltd (PBMD), OvaScience (OVAS), ReNeuron Group Plc (RENE), Bio-Path Holdings (BPTH), Senomyx (SNMX), Genocea Biosciences (GNCA), Fibrocell Science (FCSC), Abzena PLC (ABZA), Scancell Holdings Plc (SCLP) and Cleveland BioLabs (CBLI).
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Daniel N. Swisher Jr., President, Chief Executive Officer, Director
- Adam R. Craig M.D., Ph.D., Executive Vice President - Development, Chief Medical Officer
- James W. Young Ph.D., Non-Executive Independent Chairman of the Board
- Stephen B. Ketchum Ph.D., Director
- Geoffrey M. Parker, Director
- Steve R Carchedi, Independent Director
- Matthew K. Fust, Independent Director
How do I buy Sunesis Pharmaceuticals stock?
Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $1.85.
Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)Earnings History by Quarter for Sunesis Pharmaceuticals (NASDAQ SNSS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/27/2017||Q2 2017||($0.76)||($0.41)||$2.40 million||View||N/A|
|5/8/2017||Q1 2017||($0.83)||($0.47)||$1.57 million||$0.67 million||View||Listen|
|3/9/2017||Q4 2016||($0.43)||($0.44)||$0.60 million||$0.68 million||View||Listen|
|11/3/2016||Q316||($0.71)||($0.62)||$0.60 million||$0.60 million||View||N/A|
|7/29/2016||Q216||($0.10)||($0.12)||$0.70 million||$0.60 million||View||Listen|
|5/5/2016||Q116||($0.12)||($0.12)||$0.77 million||$0.64 million||View||Listen|
|3/10/2016||Q415||($0.14)||($0.15)||$0.84 million||$0.67 million||View||Listen|
|11/5/2015||Q315||($0.12)||($0.09)||$1.09 million||$0.68 million||View||Listen|
|7/30/2015||Q215||($0.13)||($0.15)||$1.21 million||$0.85 million||View||N/A|
|5/5/2015||Q115||($0.16)||($0.13)||$1.14 million||$0.90 million||View||Listen|
|3/12/2015||Q414||($0.20)||($0.02)||$1.17 million||$0.90 million||View||Listen|
|11/10/2014||Q314||($0.17)||($0.25)||$1.97 million||$0.85 million||View||Listen|
|8/5/2014||Q214||($0.17)||($0.20)||$1.32 million||$2.00 million||View||Listen|
|5/7/2014||Q114||($0.17)||($0.26)||$1.32 million||$2.00 million||View||Listen|
|3/6/2014||Q413||($0.20)||($0.15)||$1.37 million||$2.00 million||View||Listen|
|11/12/2013||Q313||($0.20)||($0.16)||$1.44 million||$1.99 million||View||Listen|
|7/29/2013||Q2 2013||($0.21)||$0.18||$1.22 million||$1.99 million||View||Listen|
|5/9/2013||Q1 2013||($0.20)||($0.23)||$0.75 million||$1.99 million||View||Listen|
|3/13/2013||Q4 2012||($0.19)||($0.20)||$0.32 million||$1.99 million||View||Listen|
|11/8/2012||Q312||($0.11)||($0.37)||$4.17 million||$0.26 million||View||N/A|
Earnings Estimates for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Current Year EPS Consensus Estimate: $-1.61 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS
Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Insider Ownership Percentage: 10.21%Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Institutional Ownership Percentage: 57.54%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/9/2016||Geoffrey M Parker||Director||Buy||3,740||$3.87||$14,473.80|| |
|5/26/2016||Geoffrey M Parker||Director||Buy||9,500||$0.47||$4,465.00|| |
|5/25/2016||Geoffrey M Parker||Director||Buy||52,505||$0.47||$24,677.35|| |
|12/21/2015||Dayton Misfeldt||Director||Buy||1,750,000||$0.84||$1,470,000.00|| |
|8/25/2015||Daniel N Swisher Jr||CEO||Buy||12,216||$1.01||$12,338.16|| |
|8/24/2015||Daniel N Swisher Jr||CEO||Buy||12,784||$1.01||$12,911.84|| |
|8/29/2014||Forest Baskett||Major Shareholder||Sell||266,700||$7.97||$2,125,599.00|| |
|8/28/2014||Bay City Capital Llc||Major Shareholder||Sell||300,700||$7.98||$2,399,586.00|| |
|8/28/2014||Dayton Misfeldt||Director||Sell||200,000||$7.89||$1,578,000.00|| |
|8/27/2014||Adam R Craig||CMO||Sell||2,554||$8.00||$20,432.00|| |
|8/27/2014||Daniel N Swisher Jr||CEO||Sell||5,000||$8.00||$40,000.00|| |
|8/27/2014||Dayton Misfeldt||Director||Sell||100,700||$8.16||$821,712.00|| |
|8/27/2014||Eric Bjerkholt||CFO||Sell||10,000||$8.00||$80,000.00|| |
|8/27/2014||Krishna Kittu Kolluri||Major Shareholder||Sell||108,300||$8.17||$884,811.00|| |
|8/12/2014||Dayton Misfeldt||Director||Sell||743,700||$6.64||$4,938,168.00|| |
|8/12/2014||Equity Opportunities Fu Growth||Major Shareholder||Sell||710,540||$6.63||$4,710,880.20|| |
Headline Trends for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Latest Headlines for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Loading headlines, please wait.
Sunesis Pharmaceuticals (SNSS) Chart for Tuesday, October, 24, 2017